| Literature DB >> 27211569 |
Aditi Bunker1, Jan Wildenhain2, Alina Vandenbergh3, Nicholas Henschke4, Joacim Rocklöv5, Shakoor Hajat6, Rainer Sauerborn4.
Abstract
INTRODUCTION: Climate change and rapid population ageing are significant public health challenges. Understanding which health problems are affected by temperature is important for preventing heat and cold-related deaths and illnesses, particularly in the elderly. Here we present a systematic review and meta-analysis on the effects of ambient hot and cold temperature (excluding heat/cold wave only studies) on elderly (65+ years) mortality and morbidity.Entities:
Keywords: Climate change; Elderly; Meta-analysis; Morbidity; Mortality; Temperature
Mesh:
Year: 2016 PMID: 27211569 PMCID: PMC4856745 DOI: 10.1016/j.ebiom.2016.02.034
Source DB: PubMed Journal: EBioMedicine ISSN: 2352-3964 Impact factor: 8.143
Descriptive study characteristics. Unique study ID corresponds to locations on Fig. 2. Exposure abbreviations: Temperature = T, Maximim = Max, Minimum = Min, Apparent Daily temperature = ADT, Mean Daily Temperature = MDT, Universal Thermal Climate Index (UTCI), Diurnal Temperature Range (DTR), PET index, (temperature, humidity, mean radiant temperature, wind speed). Additional information: RR = relative risk, CI = confidence interval, Threshold t = Threshold temperature, se = standard error. References to individual studies are listed in Supplementary file 2 (S2). Disease abbreviations: Subarachnoid haemorrhage (SAH), Intracerebral haemorrhage (IntH), Haemorrhagic stroke (HS), Cerebral infarction/Ischemic stroke (IS), Other CBD (other CBD), Stroke (unspecified as haemorrhage or infarction) (Stroke), Cerebrovascular disease (CBD), Essential hypertension (Hypertension), Ischemic heart disease (IHD), Angina (Angina), Myocardial infarction (MI), Aneurysm (Aneurysm), Pulmonary embolism (PulEmb), Heart failure (HF), Coronary atherosclerosis (CorAth), Atrio-ventricular conduction disorders (AVCD), Cardiac arrhythmias (Arrhyt), Atrial Fibrillation (AtrFib), Pulmonary heart disease (PulHD), Sudden cardiac death (SuddCD), Hypotension (Hypotension), Cardiovascular disease (CVD), Influenza and pneumonia (Flu-Pneu), Respiratory infections (InfResp), Asthma (Asthma), COPD and chronic bronchitis (COPD), Chronic lower respiratory diseases (COPD + Asthma) (CLRD), Respiratory disease (RD), Cardio-respiratory disease (Cardio-Resp), Kidney stone (KidStone), Acute renal failure (AcuteRen), Renal/genitourinary disease (GUM), Gastroenteritis (Gastro), Intestinal infection (IntInf), Infectious disease (meningitis + other inflamatory diseases) (ID), Diabetes mellitus (Diab), Endocrine diseases (Endocr), Organic mental disorders (Demen), Psychoactive substance use (Psyco), Schizophrenia (Schizo), Mental diseases (Mental), Extra-pyramidal disorders (Park), Other disorders of the nervous system (DegDis), Nervous system diseases (Nervous), Digestive system diseases (Dig), Dehydration (Dehyd), Heatstroke (HStroke), Heat related disease (Heat). 13 publications are only part of the systematic review and not the meta-analysis: IDs 4,11,23,27,29,34 apply DTR as the exposure. ID 36 presents a non-linear risk at a threshold temperature, which is not comparable to per 1 °C change in temperature. IDs 56–61 present a risk estimate as a comparison of two temperatures, also not comparable to per 1 °C change in temperature.
| Author, year | ID | Location | Time-series | Heat and/or cold effect | Exposure | Mortality or morbidity | Disease outcome and elderly age | Additional information |
|---|---|---|---|---|---|---|---|---|
| Harlan, 2014 | 1 | Arizona, USA | 2000–2008 | Heat | Max ADT | Mortality | Heat, CVD, COPD/Asthma (65 +) | Clarified this is not a heatwave paper, sample size |
| Burkart, 2014 | 2 | 26 regions, Bangladesh | 2003–2007 | Heat | UTCI | Mortality | CVD, ID (65 +) | RR, 95% CI |
| Huang, 2014 | 3 | Changsha, China | 2008–2011 | Heat | MDT | Mortality | CVD (65 +) | No |
| Yang, 2013 | 4 | Guangzhou, China | 2003–2010 | Heat and cold | DTR | Mortality | CVD, RD (65 +) | Sample size, threshold t |
| Almeida, 2013 | 5 | Lisbon and Oporto, Portugal | 2000–2004 | Heat | Max ADT | Mortality | CVD, RD (65 +) | No |
| Gasparrini, 2012 | 6 | England and Wales | 1993–2006 | Heat | Max DT | Mortality | CBD, IHD, MI, ChIHD, PulHD, AVCD, AtrFib, Arrhyt, HeartFail, CVD, InfResp, COPD, PulHD, Asthma, RD, Diab, Endocr, Demen, Schizo, Mental, Park, DegDis, Nervous, GUM, Renal (65 +) | No |
| Liu, 2011 | 7 | Beijing, China | 2003–2005 | Heat and cold | 2-day or 15-day Mean T | Mortality | CBD, IHD, CVD, RD, Cardio-Resp (65 +) | No |
| Wichmann, 2011 | 8 | Copenhagen, Denmark | 1999–2006 | Heat and cold | Max ADT | Mortality | CVD, CBD, RD (66 +) | No |
| Yu, 2011 | 9 | Brisbane, Australia | 1996–2004 | Heat and cold | MDT | Mortality | CVD (65 +) | No |
| Almeida, 2010 | 10 | Lisbon and Oporto, Portugal | 2000–2004 | Heat | Mean ADT | Mortality | CVD, RD (65 +) | No |
| Tam, 2009 | 11 | Hong Kong | 1997–2002 | Heat | DTR | Mortality | CVD (65 +) | No |
| Revich, 2008 | 12 | Moscow, Russia | 2000–2005 | Heat and cold | MDT | Mortality | IHD, CBD, CLRD (75 +) | No |
| Baccini, 2008 | 13 | 15 European cities | 1990–2000 | Heat | Max ADT | Mortality | CVD, RD (65 +) | B-estimate, se, sample size, threshold t |
| Ishigami, 2008 | 14 | Budapest, London and Milan | 1993–2004 | Heat | MDT | Mortality | CVD, RD (75 +) | No |
| Gouveia, 2003 | 15 | Sao Paulo, Brazil | 1991–1994 | Heat and cold | MDT | Mortality | CVD, RD (65 +) | Sample size |
| Wong, 2014 | 16 | Hong Kong | 2001–2005 | Cold | MDT | Mortality | RD in patients with existing hypertension (65 +) | Lag, threshold t |
| Xu, 2013 | 17 | Hong Kong | 1998–2001 | Cold | Mean ADT | Mortality | CVD, RD (65 +) | No |
| Analitis, 2008 | 18 | 15 European cities | 1990–2000 | Cold | Min ADT | Mortality | CVD, CBD, RD (65 +) | RR, CI, sample size |
| Carder, 2005 | 19 | 3 regions, Scotland | 1981–2001 | Cold | MDT | Mortality | CVD, RD (65 +) | Sample size |
| Cagle, 2005 | 20 | Washington, USA | 1980–2001 | Cold | MDT | Mortality | CVD (55 +) | No |
| Condemi, 2015 | 21 | Cuneo, Italy | 2007–2010 | Heat | MDT | Morbidity | KidStone (65 +) | No |
| Han, 2015 | 22 | Seoul, South Korea | 2004–2013 | Heat | Monthly MDT | Morbidity | CBD, IS, IntH (60 +) | No |
| Li, 2014 | 23 | Ghangzhou, China | 2010–2012 | Heat | DTR | Morbidity | InfResp (65 +) | No |
| Kim 2014 | 24 | Seoul, South Korea | 2007–2010 | Heat and cold | MDT | Morbidity | Asthma (65 +) | No |
| Giang, 2014 | 25 | Thai Nguyen, Vietnam | 2008–2012 | Heat and cold | MDT | Morbidity | CVD (60 +) | No |
| Anderson, 2013 | 26 | 213 USA counties | 1999–2008 | Heat | MDT | Morbidity | COPD, RD (65 +) | No |
| Wang, 2013 | 27 | Beijing, China | 2009–2011 | Heat | DTR | Morbidity | CVD, RD, Renal, Dig (65 +) | No |
| Chan, 2013 | 28 | Hong Kong | 1998–2009 | Heat and cold | MDT | Morbidity | RD, ID (60 +) | Sample size |
| Qiu, 2013 | 29 | Hong Kong | 2000–2007 | Heat | DTR | Morbidity | HF (65 +) | No |
| Wichmann, 2013 | 30 | Gothenburg, Sweden | 1985–2010 | Heat | Max ADT | Morbidity | AMI (66 +) | No |
| Williams, 2012 | 31 | Adelaide, Australia | 2003–2009 | Heat | Min DT | Morbidity | Renal, heat (65 +) | No |
| Goggins, 2012 | 32 | Hong Kong | 1999–2006 | Heat and cold | MDT | Morbidity | IS (65 +) | Sample size |
| Wichmann, 2012 | 33 | Copenhagen, Denmark | 1999–2006 | Heat and cold | Max ADT | Morbidity | AMI (66 +) | No |
| Lim, 2012 | 34 | 4 cities, South Korea | 2003–2006 | Heat | DTR | Morbidity | Asthma (75 +) | No |
| Basu 2012 | 35 | California, USA | 2005–2008 | Heat | Mean ADT | Morbidity | CVD, Arrhyt, Aneurysm, IHD, Hypertension, HS, IS, Hypotension, RD, AcuteRen, Hstroke, IntInf, Diab, Dehyd (65 +) | RR, CI, sample size |
| Vida, 2012 | 36 | 3 regions in Quebec, Canada | 1995–2007 | Heat | MDT | Morbidity | Mental (65 +) | Clarified effect is not per 1 °C increase in temperature |
| Silva, 2012 | 37 | Sao Paulo, Brazil | 2003–2007 | Heat and cold | Max DT | Morbidity | CVD, RD (60 +) | RR, CI |
| Alessandrini, 2011 | 38 | 9 regions Emilia-Romagna, Italy | 2002–2006 | Heat and cold | Mean ADT | Morbidity | CVD, RD (65 +) | No |
| Pudpong, 2011 | 39 | Chang Mai, Thailand | 2002–2006 | Heat | MDT | Morbidity | RD, CVD, Diab, IntInf (65 +) | Sample size |
| Morabito, 2011 | 40 | Tuscany, Italy | 1997–2006 | Heat and cold | MDT | Morbidity | SAH, IntH, IS, Stroke (65 +) | No |
| Hopstock, 2011 | 41 | Tromso, Norway | 1974–2004 | Heat | 3-day Mean T | Morbidity | MI (65 +) | Sample size |
| Wichmann, 2011 | 42 | Copenhagen, Denmark | 2002–2006 | Heat and cold | Max ADT | Morbidity | RD, CVD, CBD (66 +) | No |
| Green, 2010 | 43 | California, USA | 1999–2005 | Heat | Mean ADT | Morbidity | Flu-Pneu, IS, Dehyd, Gastro, Diab, AcuteRen (65 +) | RR, CI, sample size |
| Lin, 2009 | 44 | New York, USA | 1991–2004 | Heat | Mean ADT | Morbidity | CVD, RD (50 +) | CI, sample size |
| Michelozzi, 2009 | 45 | 12 European cities | 1990–2001 | Heat | Max ADT | Morbidity | CVD, CBD, RD (65 +) | No |
| Linares, 2008 | 46 | Madrid, Spain | 1995–2000 | Heat | Max DT | Morbidity | RD (75 +) | No |
| Kovats, 2004 | 47 | London, UK | 1994–2000 | Heat | MDT | Morbidity | RD (65 +) | Sample size |
| Koken, 2003 | 48 | Denver, USA | 19,931,997 | Heat | Max DT | Morbidity | AMI, CorAth, PulHD, Arrhyt, HF (65 +) | No |
| Liu, 2014 | 49 | Shanghai, China | 2008–2011 | Cold | MDT | Morbidity | Flu-Pneu (65 +) | No |
| Vasconcelos, 2013 | 50 | Lisbon and Opoto, Portugal | 2003–2007 | Cold | PET index | Morbidity | CVD, AMI (65 +) | No |
| Bhaskaran, 2010 | 51 | England and Wales | 2003–2006 | Cold | MDT | Morbidity | MI (65 +) | Sample size |
| Ebi, 2004 | 52 | 3 cities, California, USA | 1983–1998 | Cold | Max DT | Morbidity | CBD, AMI, Angina, HF (55 +) | No |
| Hong 2003 | 53 | Incheon, Korea | 1998 2000 | Cold | MDT | Morbidity | IS (65 +) | No |
| Hajat, 2002 | 54 | London, UK | 1992–1995 | Cold | MDT | Morbidity | RD, Asthma, Lower RD, Upper RD, CVD (65 +) | No |
| Ebi, 2001 | 55 | 3 cities, California, USA | 1983–1998 | Cold | Min DT | Morbidity | Flu-Pneu (56 +) | No |
| Breitner, 2014 | 56 | Bavaria, Germany | 1990–2006 | Heat and cold | MDT | Mortality | CVD (75 +) | No |
| Tian, 2012 | 57 | Beijing, China | 2000–2011 | Heat and cold | MDT | Mortality | Coronary heart disease (65 +) | No |
| Lin, 2011 | 58 | 4 regions, Taiwan | 1994–2007 | Heat and cold | MDT | Mortality | CVD, RD (65 +) | No |
| O′Neill 2003 | 59 | 7 counties, Chicago, USA | 1986–1993 | Heat and cold | Mean ADT | Mortality | RD, CVD (65 +) | No |
| Pan, 1995 | 60 | Taiwan | 1981–1991 | Heat and cold | MDT | Mortality | IS, IHD, HS (64 +) | No |
| Son, 2014 | 61 | 8 cities, South Korea | 2003–2008 | Heat and cold | MDT | Morbidity | Allergy, Asthma, RD, CVD (65 +) | No |
Fig. 2Distribution of A) Mortality, and B) Morbidity studies across five Köppen Geiger climate zones (A–E). Study numbers on the map (ID) are defined in Table 1. Panel A comprises mortality studies (ID 1–20, 56–60), panel B comprises morbidity studies (ID 21–55, 61). ID 56–61 represent publications with risk estimates as a comparison between two temperatures. Repeated ID numbers on the map indicates that one study presents estimates for multiple cities.
Fig. 1Prisma diagram outlining the selection procedure for mortality and morbidity articles.
Fig. 3Number of cause-specific A) mortality, and B) morbidity outcomes included in the meta-analysis.
Random-effects meta-analytic % change (and 95% confidence interval) for heat and cold related cerebrovascular, cardiovascular and respiratory mortality.
Heat outcomes correspond to percentage change per 1 °C increase in temperature above a heat threshold in summer months, across the year or as a linear risk. Cold outcomes correspond to percentage change per 1 °C decrease in temperature below a threshold in winter months, across the year or as a linear risk. Meta-analysis is conducted when k (number of city-specific risk estimates) > 2. * indicates a statistically significant percentage change at the 5% level, arrow direction = risk increase or decrease. I2 = heterogeneity score, p = p-value for the heterogeneity score.
Sample size was not obtainable for the following studies: Revich 2008 a, Ishigami 2008 b, Harlan 2014 c, Wong 2014 d.
| ICD-10 code | Cause of death (k > 2) | Mortality heat | Mortality cold | ||||
|---|---|---|---|---|---|---|---|
| % change (95% CI) | % change (95% CI) | ||||||
| I60–I69 | All cerebrovascular disease | 1.40(0.06–2.75)* | ↑ | k = 3, I2 = 70.2%, p = 0.0349, n = 224,026 | 1.21(0.66–1.77)* | ↑ | k = 14, I2 = 60.8%, p = 0.0016, n = 95,935 |
| I60–I69 I61–I62, I64 | Overall | 1.40(0.06–2.75)* | ↑ | k = 3, I2 = 70.2%, p = 0.0349, n = 224,026 | 1.21(0.66–1.77)* | ↑ | k = 14, I2 = 60.8%, p = < 0.0001, n = 95,935 |
| I20–I25 | Ischemic heart disease | 1.62(0.24–3.03)* | ↑ | k = 3, I2 = 81.5%, p = 0.0045, n = 411220a | 0.45(− 0.01–0.91) | ↑ | k = 2, I2 = 99.2%, p = < 0.0001, n = 6356 a |
| I00–I99 | All cardiovascular disease | 3.79(3.40–4.18]* | ↑ | k = 31, I2 = 99.3%, p = < 0.0001, n = 1,319,818 a, b, c | 1.84(0.85–2.84)* | ↑ | k = 24, I2 = 98.6%, p = < 0.0001, n = 688,206 a |
| I21–23, I20, I50, I00–I99, I20–I25, I27.9, I70, I26–I28, I44, I45 | Overall | 3.44(3.1–3.78)* | ↑ | k = 41, I2 = 99%, p = < 0.0001, n = 2,147,349 a, b, c | 1.66(1.19–2.14)* | ↑ | k = 26, I2 = 98.9%, p = < 0.0001, n = 694562a |
| J00–J99 | All respiratory disease | 2.32(2.02–2.62)* | ↑ | k = 26, I2 = 92.8%, p = < 0.0001, n = 367,468 | 2.90(1.84–3.97)* | ↑ | k = 22, I2 = 90.5%, p = < 0.0001, n = 168,198 a, d |
| J09–J19, J40–44, J45–J46, J00–J99 | Overall | 3.60(3.18–4.02)* | ↑ | k = 31, I2 = 97.5%, p = < 0.0001, n = 599,458 c | 2.90(1.84–3.97)* | ↑ | k = 22, I2 = 90.5%, p = < 0.0001, n = 168,198 a, d |
Random-effects meta-analytic % change (and 95% confidence interval) for heat and cold related cerebrovascular, cardiovascular, respiratory, endocrine, genitourinary, infectious and heat-related morbidity outcomes.
Heat outcomes correspond to percentage change per 1 °C increase in temperature above a heat threshold in summer months, across the year or as a linear risk. Cold outcomes correspond to percentage change per 1 °C decrease in temperature below a threshold in winter months, across the year or as a linear risk. Meta-analysis is conducted when k (number of city-specific risk estimates) > 2. * indicates a statistically significant RR at the 5% level, arrows indicate risk increase or decrease, – indicates no change in risk. I2 = heterogeneity score. Sample size was not obtainable for the following studies: Hajat 2002 a, Vasconcelos 2013 b, Alessandrini 2011 c, Michelozzi 2009 (65–74 year age group) d, Hopstock 2011 e, Alessandrini 2011 f, Williams 2012 g.
| ICD-10 code | Cause of morbidity (k > 2) | Morbidity heat | Morbidity cold | ||||
|---|---|---|---|---|---|---|---|
| % change (95% CI) | % change (95% CI) | ||||||
| I63 | Ischemic stroke | 0.33(− 0.09–0.75) | ↑ | k = 5, I2 = 84.9%, p = < 0.0001, n = 178,487 | 3.63(− 3.94–11.8) | ↑ | k = 2, I2 = 85.8%, p = 0.008, n = 39,658 |
| I61 | Intracerebral haemorrhage | − 0.66(− 2.13–0.84) | ↓ | k = 2, I2 = 88.6%, p = 0.0031, n = 10,739 | 1.49(1.04–1.94)* | ↑ | k = 2, I2 = 0%, p = 0.3908, n = 92,991 |
| I20–I25 | All cerebrovascular | − 0.17(− 0.96–0.63) | ↓ | k = 4, I2 = 46.6%,0.1318, n = 212,616 d | − 0.46(− 1.12–0.2) | ↓ | k = 8, I2 = 98.6%, p = < 0.0001, n = 552,527 |
| I60, I61, I63, I20–I25 | Overall | 0.08(− 0.01–0.17) | ↑ | k = 12 I2 = 76.9%, p = < 0.0001, n = 347,098 d | 0.05(− 0.37–0.47) | ↑ | k = 14, I2 = 97.9%, p = < 0.0001, n = 733,743 |
| I21–I23 | Myocardial infarction | − 0.16(− 2.05–1.77) | ↓ | k = 3, I2 = 73.4%, p = < 0.0001, n = 5842 e | 0.66(− 0.14–1.48) | ↑ | k = 7, I2 = 93%, p = < 0.0001, n = 339,073 b |
| I20 | Angina pectoris | NA | NA | − 0.80(− 2.21–0.64) | ↓ | k = 3, I2 = 90.1%, p = < 0.0001, n = 331,324 | |
| I50 | Heart failure | NA | NA | − 0.67(− 2.15–0.83) | ↓ | k = 3, I2 = 96.4%, p = < 0.0001, n = 457,437 | |
| I00–I99 | All cardiovascular disease | 0.30(− 0.12–0.81) | ↑ | k = 9, I2 = 93.5%, p = < 0.0001, n = 929,168 d, f | − 0.28(− 1.39–0.84) | ↓ | k = 6, I2 = 57.3%, p = < 0.0388, n = 4,371,849 a, c |
| I21–23, I20, I50, I00–I99, I20–I25, I27.9, I70 | Overall | 0.15(− 0.05–0.35) | ↑ | k = 20, I2 = 97.6%, p = < 0.0001, n = 1,015,480 d, e, f | 0.00(− 0.67–0.66) | – | k = 19, I2 = 96.6%, p = < 0.0001, n = 5,499,683 a, b, c |
| J45–J46 | Asthma | NA | NA | 3.84(− 9.38–18.99) | ↑ | k = 2, I2 = 81.2%, p = 0.0212, n = 3885 a, c | |
| J09–J18 | Pneumonia | NA | NA | 6.89(1.20–12.99)* | ↑ | k = 4, I2 = 94.5%, p = < 0.0001, n = 68,968 | |
| J00–J99 | All respiratory disease | 2.76(1.51–4.03)* | ↑ | k = 20, I2 = 82.5%, p = < 0.0001, n = 121,078 | 2.70(− 0.72–6.24) | ↑ | k = 5, I2 = 91.9%, p = < 0.0001, n = 1,267,454 f |
| J00–J99, J40–J44, J09–J18, J45–46 | Overall | 1.65(1.09–2.21)* | ↑ | k = 23, I2 = 81.4%, p = < 0.0001, n = 2,530,203 | 4.93(1.54–8.44)* | ↑ | k = 13, I2 = 97.1%, p = < 0.0001, n = 1,808,820 a, c, f |
| E10–E14 | Diabetes mellitus | 1.02(0.43–1.62)* | ↑ | k = 3, I2 = 25.3%, p = 0.2623, n = 18,393 | NA | NA | |
| N17 | Acute renal failure | 2.12(1.59–2.65)* | ↑ | k = 2, I2 = 16%, p = 0.2752, n = 26,359 | NA | NA | |
| E10–E14 | Overall | 2.12(1.65–2.59)* | ↑ | k = 4, I2 = 0%, p = 0.4613, n = 26,798 g | |||
| A00–99 | Intestinal infectious | 1.00(− 0.21–2.22) | ↑ | k = 2, I2 = 0%, p = 0.05228, n = 6064 | NA | NA | |
| A00–B99, G00–G05, N70–74, N76 | Overall | 0.76(− 0.43–1.95) | ↑ | k = 4, I2 = 27.2%, p = 0.2487, n = 148,663 | NA | NA | |
| E86 | Dehydration | 3.12(0.74–5.56)* | ↑ | k = 2, I2 = 77.7%, p = < 0.0001, n = 28,901 | NA | NA | |
| E86, T67, E70–90, X30 | Overall | 14.83(8.22–21.84)* | ↑ | k = 2, I2 = 98.3%, p = < 0.0001, n = 29,753 g | NA | NA | |